A systematic review of the pathophysiology of 5-fluorouracil-induced cardiotoxicity

Anne Polk, Kirsten Vistisen, Merete Vaage-Nilsen, Dorte L Nielsen, Anne Polk, Kirsten Vistisen, Merete Vaage-Nilsen, Dorte L Nielsen

Abstract

Background: Cardiotoxicity is a serious side effect to treatment with 5-fluorouracil (5-FU), but the underlying mechanisms are not fully understood. The objective of this systematic review was to evaluate the pathophysiology of 5-FU- induced cardiotoxicity.

Methods: We systematically searched PubMed for articles in English using the search terms: 5-FU OR 5-fluorouracil OR capecitabine AND cardiotoxicity. Papers evaluating the pathophysiology of this cardiotoxicity were included.

Results: We identified 27 articles of 26 studies concerning the pathophysiology of 5-FU-induced cardiotoxicity. The studies demonstrated 5-FU-induced: hemorrhagic infarction, interstitial fibrosis and inflammatory reaction in the myocardium; damage of the arterial endothelium followed by platelet aggregation; increased myocardial energy metabolism and depletion of high energy phosphate compounds; increased superoxide anion levels and a reduced antioxidant capacity; vasoconstriction of arteries; changes in red blood cell (RBC) structure, function and metabolism; alterations in plasma levels of substances involved in coagulation and fibrinolysis and increased endothelin-1 levels and N-terminal-pro brain natriuretic peptide levels. Based on these findings the proposed mechanisms are: endothelial injury followed by thrombosis, increased metabolism leading to energy depletion and ischemia, oxidative stress causing cellular damage, coronary artery spasm leading to myocardial ischemia and diminished ability of RBCs to transfer oxygen resulting in myocardial ischemia.

Conclusions: There is no evidence for a single mechanism responsible for 5-FU-induced cardiotoxicity, and the underlying mechanisms might be multifactorial. Further research is needed to elucidate the pathogenesis of this side effect.

Figures

Figure 1
Figure 1
Study identification and selection process.

References

    1. Malet-Martino M, Jolimaitre P, Martino R. The prodrugs of 5-fluorouracil. Curr Med Chem Anticancer Agents. 2002;2:267–310. doi: 10.2174/1568011023354146.
    1. Polk A, Vaage-Nilsen M, Vistisen K, Nielsen DL. Cardiotoxicity in cancer patients treated with 5-fluorouracil or capecitabine: A systematic review of incidence, manifestations and predisposing factors. Cancer Treat Rev. 2013;39:974–84. doi: 10.1016/j.ctrv.2013.03.005.
    1. Kosmas C, Kallistratos MS, Kopterides P, Syrios J, Skopelitis H, Mylonakis N, Karabelis A, Tsavaris N. Cardiotoxicity of fluoropyrimidines in different schedules of administration: a prospective study. J Cancer Res Clin Oncol. 2008;134:75–82.
    1. Meydan N, Kundak I, Yavuzsen T, Oztop I, Barutca S, Yilmaz U, Alakavuklar MN. Cardiotoxicity of de Gramont’s regimen: incidence, clinical characteristics and long-term follow-up. Jpn J Clin Oncol. 2005;35:265–270. doi: 10.1093/jjco/hyi071.
    1. Meyer CC, Calis KA, Burke LB, Walawander CA, Grasela TH. Symptomatic cardiotoxicity associated with 5-fluorouracil. Pharmacotherapy. 1997;17:729–736.
    1. Ng M, Cunningham D, Norman AR. The frequency and pattern of cardiotoxicity observed with capecitabine used in conjunction with oxaliplatin in patients treated for advanced colorectal cancer (CRC) Eur J Cancer. 2005;41:1542–1546. doi: 10.1016/j.ejca.2005.03.027.
    1. Rezkalla S, Kloner RA, Ensley J, al-Sarraf M, Revels S, Olivenstein A, Bhasin S, Kerpel-Fronious S, Turi ZG. Continuous ambulatory ECG monitoring during fluorouracil therapy: a prospective study. J Clin Oncol. 1989;7:509–514.
    1. Jensen SA, Sorensen JB. 5-fluorouracil-based therapy induces endovascular injury having potential significance to development of clinically overt cardiotoxicity. Cancer Chemother Pharmacol. 2012;69:57–64. doi: 10.1007/s00280-011-1669-x.
    1. Kinhult S, Albertsson M, Eskilsson J, Cwikiel M. Antithrombotic treatment in protection against thrombogenic effects of 5-fluorouracil on vascular endothelium: a scanning microscopy evaluation. Scanning. 2001;23:1–8.
    1. Kuzel T, Esparaz B, Green D, Kies M. Thrombogenicity of intravenous 5-fluorouracil alone or in combination with cisplatin. Cancer. 1990;65:885–889. doi: 10.1002/1097-0142(19900215)65:4<885::AID-CNCR2820650410>;2-H.
    1. Lemaire L, Malet-Martino MC, De ᅟ FM, Martino R, Lasserre B. Cardiotoxicity of commercial 5-fluorouracil vials stems from the alkaline hydrolysis of this drug. Br J Cancer. 1992;66:119–127. doi: 10.1038/bjc.1992.227.
    1. Matsubara I, Kamiya J, Imai S. Cardiotoxic effects of 5-fluorouracil in the guinea pig. Jpn J Pharmacol. 1980;30:871–879. doi: 10.1254/jjp.30.871.
    1. Tsavaris N, Kosmas C, Vadiaka M, Efremidis M, Zinelis A, Beldecos D, Sakelariou D, Koufos C, Stamatelos G. Cardiotoxicity following different doses and schedules of 5-fluorouracil administration for malignancy – a survey of 427 patients. Med Sci Monit. 2002;8:I51–I57.
    1. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6:e1000097. doi: 10.1371/journal.pmed.1000097.
    1. Kumar S, Gupta RK, Samal N. 5-fluorouracil induced cardiotoxicity in albino rats. Mater Med Pol. 1995;27:63–66.
    1. Tsibiribi P, Bui-Xuan C, Bui-Xuan B, Lombard-Bohas C, Duperret S, Belkhiria M, Tabib A, Maujean G, Descotes J, Timour Q. Cardiac lesions induced by 5-fluorouracil in the rabbit. Hum Exp Toxicol. 2006;25:305–309. doi: 10.1191/0960327106ht628oa.
    1. Lamberti M, Porto S, Marra M, Zappavigna S, Grimaldi A, Feola D, Pesce D, Naviglio S, Spina A, Sannolo N, Caraglia M. 5-Fluorouracil induces apoptosis in rat cardiocytes through intracellular oxidative stress. J Exp Clin Cancer Res. 2012;31:60. doi: 10.1186/1756-9966-31-60.
    1. Durak I, Karaayvaz M, Kavutcu M, Cimen MY, Kacmaz M, Buyukkocak S, Ozturk HS. Reduced antioxidant defense capacity in myocardial tissue from guinea pigs treated with 5-fluorouracil. J Toxicol Environ Health A. 2000;59:585–589. doi: 10.1080/009841000156709.
    1. Millart H, Kantelip JP, Platonoff N, Descous I, Trenque T, Lamiable D, Choisy H. Increased iron content in rat myocardium after 5-fluorouracil chronic administration. Anticancer Res. 1993;13:779–783.
    1. Millart H, Brabant L, Lorenzato M, Lamiable D, Albert O, Choisy H. The effects of 5-fluorouracil on contractility and oxygen uptake of the isolated perfused rat heart. Anticancer Res. 1992;12:571–576.
    1. Satoh H, Hashimoto K. Effects of ftorafur and 5-fluorouracil on the canine sinoatrial node. Jpn J Pharmacol. 1983;33:357–362. doi: 10.1254/jjp.33.357.
    1. Cwikiel M, Zhang B, Eskilsson J, Wieslander JB, Albertsson M. The influence of 5-fluorouracil on the endothelium in small arteries. An electron microscopic study in rabbits. Scanning Microsc. 1995;9:561–576.
    1. Cwikiel M, Eskilsson J, Wieslander JB, Stjernquist U, Albertsson M. The appearance of endothelium in small arteries after treatment with 5-fluorouracil. An electron microscopic study of late effects in rabbits. Scanning Microsc. 1996;10:805–818.
    1. Kinhult S, Albertsson M, Eskilsson J, Cwikiel M. Effects of probucol on endothelial damage by 5-fluorouracil. Acta Oncol. 2003;42:304–308. doi: 10.1080/02841860310004409.
    1. Cwikiel M, Eskilsson J, Albertsson M, Stavenow L. The influence of 5-fluorouracil and methotrexate on vascular endothelium. An experimental study using endothelial cells in the culture. Ann Oncol. 1996;7:731–737. doi: 10.1093/oxfordjournals.annonc.a010723.
    1. Mosseri M, Fingert HJ, Varticovski L, Chokshi S, Isner JM. In vitro evidence that myocardial ischemia resulting from 5-fluorouracil chemotherapy is due to protein kinase C-mediated vasoconstriction of vascular smooth muscle. Cancer Res. 1993;53:3028–3033.
    1. Salepci T, Seker M, Uyarel H, Gumus M, Bilici A, Ustaalioglu BB, Ozturk A, Sonmez B, Orcun A, Ozates M, Irmak R, Yaylaci M. 5-Fluorouracil induces arterial vasoconstrictions but does not increase angiotensin II levels. Med Oncol. 2010;27:416–420. doi: 10.1007/s12032-009-9226-8.
    1. Sudhoff T, Enderle MD, Pahlke M, Petz C, Teschendorf C, Graeven U, Schmiegel W. 5-Fluorouracil induces arterial vasocontractions. Ann Oncol. 2004;15:661–664. doi: 10.1093/annonc/mdh150.
    1. Baerlocher GM, Beer JH, Owen GR, Meiselman HJ, Reinhart WH. The anti-neoplastic drug 5-fluorouracil produces echinocytosis and affects blood rheology. Br J Haematol. 1997;99:426–432. doi: 10.1046/j.1365-2141.1997.4003212.x.
    1. Spasojevic I, Maksimovic V, Zakrzewska J, Bacic G. Effects of 5-fluorouracil on erythrocytes in relation to its cardiotoxicity: membrane structure and functioning. J Chem Inf Model. 2005;45:1680–1685. doi: 10.1021/ci0501746.
    1. Spasojevic I, Zakrzewska J, Bacic GG. 31P NMR spectroscopy and polarographic combined study of erythrocytes treated with 5-fluorouracil: cardiotoxicity-related changes in ATP, 2,3-BPG, and O2 metabolism. Ann N Y Acad Sci. 2005;1048:311–320. doi: 10.1196/annals.1342.028.
    1. Spasojevic I, Jelic S, Zakrzewska J, Bacic G. Decreased oxygen transfer capacity of erythrocytes as a cause of 5-fluorouracil related ischemia. Molecules. 2009;14:53–67.
    1. Cwikiel M, Persson SU, Larsson H, Albertsson M, Eskilsson J. Changes of blood viscosity in patients treated with 5-fluorouracil–a link to cardiotoxicity? Acta Oncol. 1995;34:83–85.
    1. Jensen SA, Hasbak P, Mortensen J, Sorensen JB. Fluorouracil induces myocardial ischemia with increases of plasma brain natriuretic peptide and lactic acid but without dysfunction of left ventricle. J Clin Oncol. 2010;28:5280–5286. doi: 10.1200/JCO.2009.27.3953.
    1. Thyss A, Gaspard MH, Marsault R, Milano G, Frelin C, Schneider M. Very high endothelin plasma levels in patients with 5-FU cardiotoxicity. Ann Oncol. 1992;3:88.
    1. Wenzel DG, Cosma GN. A model system for measuring comparative toxicities of cardiotoxic drugs for cultured rat heart myocytes, endothelial cells and fibroblasts. II. Doxorubicin, 5-fluorouracil and cyclophosphamide. Toxicology. 1984;33:117–128. doi: 10.1016/0300-483X(84)90067-2.
    1. Tamatsu H, Nakazawa M, Imai S, Watari H. 31P-topical nuclear magnetic resonance (31P-TMR) studies of cardiotoxic effects of 5-fluorouracil (5-FU) and 5′-deoxy-5-fluorouridine (5′-DFUR) Jpn J Pharmacol. 1984;34:375–379. doi: 10.1254/jjp.34.375.
    1. Barnabe N, Zastre JA, Venkataram S, Hasinoff BB. Deferiprone protects against doxorubicin-induced myocyte cytotoxicity. Free Radic Biol Med. 2002;33:266–275. doi: 10.1016/S0891-5849(02)00873-0.
    1. Hasinoff BB, Patel D, Wu X. The oral iron chelator ICL670A (deferasirox) does not protect myocytes against doxorubicin. Free Radic Biol Med. 2003;35:1469–1479. doi: 10.1016/j.freeradbiomed.2003.08.005.
    1. Hershko C, Link G, Tzahor M, Pinson A. The role of iron and iron chelators in anthracycline cardiotoxicity. Leuk Lymphoma. 1993;11:207–214. doi: 10.3109/10428199309086997.
    1. Kang YJ, Zhou ZX, Wang GW, Buridi A, Klein JB. Suppression by metallothionein of doxorubicin-induced cardiomyocyte apoptosis through inhibition of p38 mitogen-activated protein kinases. J Biol Chem. 2000;275:13690–13698. doi: 10.1074/jbc.275.18.13690.
    1. Kim DS, Kim HR, Woo ER, Hong ST, Chae HJ, Chae SW. Inhibitory effects of rosmarinic acid on adriamycin-induced apoptosis in H9c2 cardiac muscle cells by inhibiting reactive oxygen species and the activations of c-Jun N-terminal kinase and extracellular signal-regulated kinase. Biochem Pharmacol. 2005;70:1066–1078. doi: 10.1016/j.bcp.2005.06.026.
    1. Kwok JC, Richardson DR. Unexpected anthracycline-mediated alterations in iron-regulatory protein-RNA-binding activity: the iron and copper complexes of anthracyclines decrease RNA-binding activity. Mol Pharmacol. 2002;62:888–900. doi: 10.1124/mol.62.4.888.
    1. Minotti G, Ronchi R, Salvatorelli E, Menna P, Cairo G. Doxorubicin irreversibly inactivates iron regulatory proteins 1 and 2 in cardiomyocytes: evidence for distinct metabolic pathways and implications for iron-mediated cardiotoxicity of antitumor therapy. Cancer Res. 2001;61:8422–8428.
    1. L’Ecuyer T, Horenstein MS, Thomas R, Vander HR. Anthracycline-induced cardiac injury using a cardiac cell line: potential for gene therapy studies. Mol Genet Metab. 2001;74:370–379. doi: 10.1006/mgme.2001.3243.
    1. Sawyer DB, Fukazawa R, Arstall MA, Kelly RA. Daunorubicin-induced apoptosis in rat cardiac myocytes is inhibited by dexrazoxane. Circ Res. 1999;84:257–265. doi: 10.1161/01.RES.84.3.257.
    1. Ozturk MA, Ozveren O, Cinar V, Erdik B, Oyan B. Takotsubo syndrome: an underdiagnosed complication of 5-fluorouracil mimicking acute myocardial infarction. Blood Coagul Fibrinolysis. 2013;24:90–94. doi: 10.1097/MBC.0b013e3283597605.
    1. Kim SM, Kwak CH, Lee B, Kim SB, Sir JJ, Cho WH, Choi SK. A case of severe coronary spasm associated with 5-fluorouracil chemotherapy. Korean J Intern Med. 2012;27:342–345. doi: 10.3904/kjim.2012.27.3.342.
    1. Tsiamis E, Synetos A, Stefanadis C. Capecitabine may induce coronary artery vasospasm. Hellenic J Cardiol. 2012;53:320–323.
    1. Shah NR, Shah A, Rather A. Ventricular fibrillation as a likely consequence of capecitabine-induced coronary vasospasm. J Oncol Pharm Pract. 2012;18:132–135. doi: 10.1177/1078155211399164.
    1. Basselin C, Fontanges T, Descotes J, Chevalier P, Bui-Xuan B, Feinard G, Timour Q. 5-Fluorouracil-induced Tako-Tsubo-like syndrome. Pharmacotherapy. 2011;31:226. doi: 10.1592/phco.31.2.226.
    1. Calik AN, Celiker E, Velibey Y, Cagdas M, Guzelburc O. Initial dose effect of 5-fluorouracil: rapidly improving severe, acute toxic myopericarditis. Am J Emerg Med. 2012;30:257–3.
    1. Atar A, Korkmaz ME, Ozin B. Two cases of coronary vasospasm induced by 5-fluorouracil. Anadolu Kardiyol Derg. 2010;10:461–462. doi: 10.5152/akd.2010.147.
    1. Tajik R, Saadat H, Taherkhani M, Movahed MR. Angina induced by 5-fluorouracil infusion in a patient with normal coronaries. Am Heart Hosp J. 2010;8:E111–E112. doi: 10.15420/ahhj.2010.8.2.111.
    1. Camaro C, Danse PW, Bosker HA. Acute chest pain in a patient treated with capecitabine. Neth Heart J. 2009;17:288–291. doi: 10.1007/BF03086268.
    1. Gianni M, Dentali F, Lonn E. 5 flourouracil-induced apical ballooning syndrome: a case report. Blood Coagul Fibrinolysis. 2009;20:306–308. doi: 10.1097/MBC.0b013e328329e431.
    1. Yung LT, McCrea WA. Capecitabine induced acute coronary syndrome. BMJ Case Rep. 2009;2009
    1. Scott PA, Ferchow L, Hobson A, Curzen NP. Coronary spasm induced by capecitabine mimicks ST elevation myocardial infarction. Emerg Med J. 2008;25:699–700. doi: 10.1136/emj.2008.060574.
    1. Canale ML, Camerini A, Stroppa S, Porta RP, Caravelli P, Mariani M, Balbarini A, Ricci S. A case of acute myocardial infarction during 5-fluorouracil infusion. J Cardiovasc Med (Hagerstown) 2006;7:835–837. doi: 10.2459/01.JCM.0000250874.09273.9b.
    1. Cardinale D, Colombo A, Colombo N. Acute coronary syndrome induced by oral capecitabine. Can J Cardiol. 2006;22:251–253. doi: 10.1016/S0828-282X(06)70905-9.
    1. Mafrici A, Alberti A, Corrada E, Ferrari S, Marenna B. Management of patients with persistent chest pain and ST-segment elevation during 5-fluorouracil treatment: report about two cases. Ital Heart J. 2003;4:895–899.
    1. McGlinchey PG, Webb ST, Campbell NP. 5-fluorouracil-induced cardiotoxicity mimicking myocardial infarction: a case report. BMC Cardiovasc Disord. 2001;1:3. doi: 10.1186/1471-2261-1-3.
    1. Schnetzler B, Popova N, Collao LC, Sappino AP. Coronary spasm induced by capecitabine. Ann Oncol. 2001;12:723–724.
    1. Prandoni P, Falanga A, Piccioli A. Cancer and venous thromboembolism. Lancet Oncol. 2005;6:401–410. doi: 10.1016/S1470-2045(05)70207-2.
    1. Okholm M, Iversen LH, Thorlacius-Ussing O, Ejlersen E, Boesby S. Fibrin and fibrinogen degradation products in plasma of patients with colorectal adenocarcinoma. Dis Colon Rectum. 1996;39:1102–1106. doi: 10.1007/BF02081408.
    1. Oya M, Akiyama Y, Okuyama T, Ishikawa H. High preoperative plasma D-dimer level is associated with advanced tumor stage and short survival after curative resection in patients with colorectal cancer. Jpn J Clin Oncol. 2001;31:388–394. doi: 10.1093/jjco/hye075.
    1. Blackwell K, Hurwitz H, Lieberman G, Novotny W, Snyder S, Dewhirst M, Greenberg C. Circulating D-dimer levels are better predictors of overall survival and disease progression than carcinoembryonic antigen levels in patients with metastatic colorectal carcinoma. Cancer. 2004;101:77–82. doi: 10.1002/cncr.20336.
    1. Iversen LH, Okholm M, Thorlacius-Ussing O. Pre- and postoperative state of coagulation and fibrinolysis in plasma of patients with benign and malignant colorectal disease–a preliminary study. Thromb Haemost. 1996;76:523–528.
    1. Damin DC, Rosito MA, Gus P, Roisemberg I, Bandinelli E, Schwartsmann G. Von Willebrand factor in colorectal cancer. Int J Colorectal Dis. 2002;17:42–45. doi: 10.1007/s003840100345.
    1. Rohsig LM, Damin DC, Stefani SD, Castro CG Jr, Roisenberg I, Schwartsmann G. von Willebrand factor antigen levels in plasma of patients with malignant breast disease. Braz J Med Biol Res. 2001;34:1125–1129. doi: 10.1590/S0100-879X2001000900004.
    1. Gil-Bazo I, Catalan G,V, Alonso GA, Rodriguez RJ, Paramo Fernandez JA, de la Camara GJ, Hernandez Lizoain JL, Garcia-Foncillas LJ. Impact of surgery and chemotherapy on von Willebrand factor and vascular endothelial growth factor levels in colorectal cancer. Clin Transl Oncol. 2005;7:150–155. doi: 10.1007/BF02708752.
    1. Wang WS, Lin JK, Lin TC, Chiou TJ, Liu JH, Yen CC, Chen PM. Plasma von Willebrand factor level as a prognostic indicator of patients with metastatic colorectal carcinoma. World J Gastroenterol. 2005;11:2166–2170.
    1. Suzuki T, Nakanishi H, Hayashi A. Cardiac toxicity of 5-fluorouracil in rabbits. Jpn J Pharmacol. 1977;27 s:137. Ref Type: Abstract.
    1. Sterba M, Popelova O, Vavrova A, Jirkovsky E, Kovarikova P, Gersl V, Simunek T. Oxidative stress, redox signaling, and metal chelation in anthracycline cardiotoxicity and pharmacological cardioprotection. Antioxid Redox Signal. 2013;18:899–929. doi: 10.1089/ars.2012.4795.
    1. Kehrer JP. The Haber-Weiss reaction and mechanisms of toxicity. Toxicology. 2000;149:43–50. doi: 10.1016/S0300-483X(00)00231-6.
    1. Nielsen F, Mikkelsen BB, Nielsen JB, Andersen HR, Grandjean P. Plasma malondialdehyde as biomarker for oxidative stress: reference interval and effects of life-style factors. Clin Chem. 1997;43:1209–1214.
    1. Li T, Danelisen I, Bello-Klein A, Singal PK. Effects of probucol on changes of antioxidant enzymes in adriamycin-induced cardiomyopathy in rats. Cardiovasc Res. 2000;46:523–530. doi: 10.1016/S0008-6363(00)00039-0.
    1. Siveski-Iliskovic N, Kaul N, Singal PK. Probucol promotes endogenous antioxidants and provides protection against adriamycin-induced cardiomyopathy in rats. Circulation. 1994;89:2829–2835. doi: 10.1161/01.CIR.89.6.2829.
    1. Kaul N, Siveski-Iliskovic N, Thomas TP, Hill M, Khaper N, Singal PK. Probucol improves antioxidant activity and modulates development of diabetic cardiomyopathy. Nutrition. 1995;11:551–554.
    1. Alter P, Herzum M, Soufi M, Schaefer JR, Maisch B. Cardiotoxicity of 5-fluorouracil. Cardiovasc Hematol Agents Med Chem. 2006;4:1–5.
    1. Shoemaker LK, Arora U, Rocha Lima CM. 5-fluorouracil-induced coronary vasospasm. Cancer Control. 2004;11:46–49.
    1. Luwaert RJ, Descamps O, Majois F, Chaudron JM, Beauduin M. Coronary artery spasm induced by 5-fluorouracil. Eur Heart J. 1991;12:468–470.
    1. Schwartz BG, Economides C, Mayeda GS, Burstein S, Kloner RA. The endothelial cell in health and disease: its function, dysfunction, measurement and therapy. Int J Impot Res. 2010;22:77–90. doi: 10.1038/ijir.2009.59.
    1. Nishizuka Y. Studies and perspectives of protein kinase C. Science. 1986;233:305–312. doi: 10.1126/science.3014651.
    1. Levin ER. Endothelins. N Engl J Med. 1995;333:356–363. doi: 10.1056/NEJM199508103330607.
    1. Khimji AK, Rockey DC. Endothelin–biology and disease. Cell Signal. 2010;22:1615–1625. doi: 10.1016/j.cellsig.2010.05.002.
    1. MacCarthy PA, Pegge NC, Prendergast BD, Shah AM, Groves PH. The physiological role of endogenous endothelin in the regulation of human coronary vasomotor tone. J Am Coll Cardiol. 2001;37:137–143. doi: 10.1016/S0735-1097(00)01042-1.
    1. Kinlay S, Behrendt D, Wainstein M, Beltrame J, Fang JC, Creager MA, Selwyn AP, Ganz P. Role of endothelin-1 in the active constriction of human atherosclerotic coronary arteries. Circulation. 2001;104:1114–1118. doi: 10.1161/hc3501.095707.
    1. Arellano M, Malet-Martino M, Martino R, Gires P. The anti-cancer drug 5-fluorouracil is metabolized by the isolated perfused rat liver and in rats into highly toxic fluoroacetate. Br J Cancer. 1998;77:79–86. doi: 10.1038/bjc.1998.12.
    1. Sasson Z, Morgan CD, Wang B, Thomas G, MacKenzie B, Platts ME. 5-Fluorouracil related toxic myocarditis: case reports and pathological confirmation. Can J Cardiol. 1994;10:861–864.

Source: PubMed

스폰서 및 공동 작업자

건강 상태

약물 개입

3
구독하다